$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Why is neratinib recommended to be taken with food?
2026-02-01 22:25:32
Check Details
Neratinib Maleate Patient Medication Guide
2026-02-01 22:25:32
Check Details
Efficacy and survival of brigatinib/brigatinib
2026-02-01 22:25:32
Check Details
Brigatinib/Brigatinib generally has no progression period for several years
2026-02-01 22:25:32
Check Details
Which one is better: brigatinib/brigatinib or aletinib?
2026-02-01 22:25:32
Check Details
Which one is better: brigatinib/brigatinib or lorlatinib?
2026-02-01 22:25:32
Check Details
How much does it cost to take brigatinib/brigatinib a month?
2026-02-01 22:25:32
Check Details
What is the difference between brigatinib/brigatinib and osimertinib?
2026-02-01 22:25:32
Check Details
Study on the progression-free phase of brigatinib/brigatinib in the treatment of ALK-positive non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Brigatinib/Brigatinib vs. Alectinib: The debate over which one is better for ALK-positive non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Brigatinib/Brigatinib vs. Lorlatinib: Comparison of Two ALK Inhibitors
2026-02-01 22:25:32
Check Details
Brigatinib/Brigatinib vs. Osimertinib: An in-depth comparison of two lung cancer drugs
2026-02-01 22:25:32
Check Details
1
2
...
661
662
663
664
665
666
667
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
2
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
3
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
4
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
8
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
9
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
10
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
11
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
12
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors